Cleveland Clinic Cancer Institute provides complete cancer care enhanced by innovative basic, clinical and translational research. It offers the most effective techniques to achieve long-term survival and improve patients’ quality of life. Cleveland Clinic Cancer Institute’s more than 800 physicians, researchers, nurses and technicians care for thousands of patients each year and provide access to a wide range of clinical trials. Cleveland Clinic Cancer Institute has a global presence, uniting clinicians based in our Cancer Institute, Cleveland Clinic’s other patient-centered institutes, our regional hospitals and health centers, and our operations in Florida, London and Abu Dhabi. Cleveland Clinic is a nonprofit, multi-specialty academic medical center with more than 5,000 staff physicians and researchers who integrate outpatient and hospital care with research and education for better patient outcomes and experience. Cleveland Clinic is a trusted healthcare leader. We’re recognized in the U.S. and throughout the world for our expertise and care.
Be sure to tune into our Cancer Advances podcast where we explore the latest innovative research and clinical advances in the field of oncology. Listen now!
Clinical Benefits With Neratinib in HER2+ Early Breast Cancer
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.
AE Management With Neratinib in HER2+ Early Breast Cancer
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer.
Evolving and Current Standards of Care for HER2+ Early Breast Cancer
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.
Prognosis and Survival Outcomes for HER2+ Early Breast Cancer
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.
Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials
February 9th 2024Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.
Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE
January 26th 2024Panel experts examine considerations for BTKi-based strategies in R/R CLL, highlighting pivotal findings from head-to-head trials, including acalabrutinib vs ibrutinib in ELEVATE-RR and zanubrutinib vs ibrutinib in ALPINE, covering safety, quality of life, and extended follow-up data.
Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy
January 19th 2024Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.
Exploring the Role of BTKi-Based Combination Therapies for Front-line Management of CLL
January 19th 2024Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).